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Abstract 
Non-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2)-selective 
NSAIDs, are associated with adverse effects on bone tissue. These drugs are frequently the 
treatment of choice but are the least studied with respect to their repercussion on bone. The 
objective of this study was to determine the effects of celecoxib on cultured human osteoblasts. 
Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at 
doses of 0.75, 2, or 5µM for 24 h. The MTT technique was used to determine the effect on 
proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile; 
and real-time polymerase chain reaction to measure the effect on gene expressions of the 
differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX). 
Therapeutic doses of celecoxib had no effect on osteoblast cell growth or antigen expression but 
had a negative impact on the gene expression of RUNX2 and OSC, although there was no significant 
change in the expression of ALP and OSX. Celecoxib at therapeutic doses has no apparent adverse 
effects on cultured human osteoblasts and only inhibits the expression of some differentiation 
markers. These characteristics may place this drug in a preferential position among NSAIDs used for 
analgesic and anti-inflammatory therapy during bone tissue repair. 
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Introduction 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) include a large group of drugs that inhibit 
the cyclooxygenase enzyme (COX). These are divided 
between non-selective and selective inhibitors of 
COX-2 and are widely used in clinical practice to 
control pain and inflammation, especially in 
orthopedics and bone surgery (1,2). 
Various in vitro studies have found that NSAIDs 
exert adverse effects on the physiology of osteoblasts, 
including: inhibition of their proliferative capacity and 
cell differentiation; alteration of their antigenic profile; 
and modulation of the gene expression of markers 
involved in cell growth and maturation and bone 
mineralization (3–9). In parallel, various in vivo studies 
have shown that these drugs affect bone tissue though 
a delay in bony callus formation in fractures (10,11) or 
a loss of bone mineral density (12), among others. 
However, research to date has mainly focused on 
non-selective NSAIDs.  








on bone tissue have largely been conducted in animal 
models and murine cell lines (13). There are currently 
no conclusive data on celecoxib, a potent selective 
NSAID mainly used in orthopedics and 
rheumatology. Some authors reported its adverse 
effects on bone formation in animal models (14), 
whereas others observed no celecoxib-related bone 
involvement (15).  
The objective of this study was to determine the 
impact of celecoxib on cultured human osteoblasts by 
analyzing the effect of different celecoxib doses on the 
growth, antigenic profile, and gene expression of 
human osteoblasts obtained by primary culture from 
bone samples. 
Material and methods  
Primary Human Osteoblast 
Human bone tissue was obtained from the 
Department of Stomatology of the University of 
Granada. All participants provided written informed 
consent to participate in this study, which was 
approved by the Ethical Committee of the University 
of Granada (Reg. No. 524/CEIH/2018). Primary 
osteoblasts were harvested from anonymous tissue in 
bone chips gathered during mandibular osteotomy or 
the surgical removal of lower wisdom teeth. We 
included a total of 3 donors in order to do all the 
assays for triplicate; 2 male and 1 female (30, 26 and 27 
years old respectively). These cells were collected and 
cultured according to a standardized protocol (9), 
establishing three cell lines of primary culture human 
osteoblasts cultured. Cells were cultured until passage 
4 to 6 before the treatment. 
Treatments 
The osteoblastic cell lines were treated for 24 h 
with celecoxib (Sigma, St Louis, MO, USA) at doses of 
0.75, 2, or 5 μM; untreated cells served as controls. 
Cell proliferation 
Cell proliferation was determined by the MTT 
method as reported by Illescas-Montes et al. (16). 
Osteoblasts were seeded at 1 x 104 cells/mL per well 
into a 96-well plate without fetal bovine serum (FBS) 
and cultured at 37 ºC for 24 h. The medium was then 
replaced with Dulbecco´s Modified Eagle medium 
(DMEM) containing celecoxib at a dose of 0.75, 2, or 5 
μM. After 24 h, the medium was replaced with DMEM 
containing 0.5 mg/mL MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) supplied by Sigma and incubated for 4 h. 
Cellular reduction of the MTT tetrazolium ring 
resulted in the formation of a dark-purple 
water-insoluble deposit of formazan crystals. After 
incubation, the medium was aspirated and DMSO 
was added to dissolve the formazan crystals. 
Absorbance was measured at 570 nm with a 
spectrophotometer (SunriseTM, Tecan, Männedorf, 
Switzerland).  
Cell Cycle 
Cultured human osteoblast cells treated with 
0.75, 2, or 5 μM celecoxib or with no NSAID treatment 
(controls) were detached from the culture flask with a 
solution of 0.05 % trypsin (Sigma) and 0.02 % ethylene 
diamine tetraacetic acid (EDTA) (Sigma) and were 
then washed and suspended in phosphate buffered 
saline (PBS) and prepared for the cell cycle study by 
flow cytometry as previously reported (16).  
Apoptosis and necrosis analysis 
Cultured human osteoblast cells treated with 
0.75, 2, or 5 μM celecoxib for 24 h or with no NSAID 
treatment (controls) were detached from the culture 
flask, washed, suspended in 300 µL PBS, and then 
labeled with annexin V and propidium iodide (PI) 
(Immunostep S.L., Salamanca, Spain). We incubated 
100 µL aliquots of the cell suspension with 5 µL 
annexin V and 5 µL PI for 30 min at 4 ºC in the dark. 
Cells were then washed, suspended in 1 mL PBS, and 
immediately analyzed in a flow cytometer with argon 
laser (Fasc Vantage Becton Dickinson, Palo Alto, CA) 
at a wavelength of 488 nm to determine the percentage 
of fluorescent cells. We calculated the percentage of 
annexin-positive (apoptotic) cells and PI-positive 
(necrotic) cells from counts of 2,000-3,000 cells.  
Antigenic phenotype 
Antigenic phenotype was studied by flow 
cytometry at 24 h of culture after treatment with 0.75, 
2, or 5 μM celecoxib. Untreated cells served as 
controls. Cells were detached from the cultured flask 
with 0.4 % (w/v) EDTA solution, washed, and 
suspended in PBS at 2×104 cells/mL. Cells were 
labeled by direct staining with the monoclonal 
antibodies (MAbs) CD54, CD80, CD86, and HLA-DR 
(ICAM-1 monoclonal antibody [MEM-111], FITC; 
human CD80 [B7-1, BB1], FICT; human CD86 [B7-2, 
B70], FICT; and anti-human HLA-DR [Clas II], FICT; 
respectively, from Invitrogen, Thermo Fisher 
Scientific, Spain). Cells were subsequently analyzed 
by flow cytometry (FASC Canton II, SE Becton 
Dickinson, Palo Alto, CA) as previously described 
Melguizo-Rodriguez et al. (8).  
Gene expression determination by real-time 
polymerase chain reaction (RT-qPCR) 
Gene expression analysis was performed as 
described Bustin et al. (17), Manzano-Moreno et al. 




(18) and Ragni et al. (19):  
RNA extraction and cDNA synthesis (reverse 
transcription) 
After 24 h of culture with Celecoxib treatment 
(untreated cells served as controls), cells were 
detached from the culture flask using 0.05% 
trypsin-EDTA solution (Sigma) and individually 
harvested. mRNA was extracted using a silicate gel 
technique in the QiagenRNeasy extraction kit (Qiagen 
Inc., Hilden, Germany), which includes a DNAse 
digestion step. The amount of extracted mRNA was 
measured by UV spectrophotometry at 260 nm 
(Eppendorf AG, Hamburg, Germany), and 
contamination with proteins was determined 
according to the 260/280 ratio. An equal amount of 
RNA (1 μg of total RNA in 40 μl of total volume) was 
reverse-transcribed to cDNA and amplified by PCR 
using the iScript™ cDNA Synthesis Kit (Bio-Rad 
laboratories, Hercules, CA, USA), following the 
manufacturer`s instructions. 
Real-time polymerase chain reaction 
(RT-PCR) 
Primers were designed using NCBI-nucleotide 
library and Primer3-design (Table 1) to detect mRNA 
of RUNX2, OSC, OSX, and ALP. All were matched to 
the mRNA sequences of target genes (NCBI Blast 
software).  
Final results were normalized using ubiquitin C 
(UBC), peptidylprolyl isomerase A (PPIA), and 
ribosomal protein S13 (RPS13) as stable housekeeping 
genes. 
Quantitative RT-PCR (q-RT-PCR) was conducted 
using the SsoFast™ EvaGreen® Supermix Kit 
(Bio-Rad laboratories) and following the 
manufacturer`s instructions. Samples were amplified 
in 96-well microplates in an IQ5-Cycler (Bio-Rad 
laboratories) at a specific annealing temperature for 
each gene, ranging from 60 to 65 ºC, and at an 
elongation temperature of 72 °C over 40 cycles. PCR 
reactions were carried out in a final volume of 20 μL, 
with 5 μL of cDNA sample and 2 μL of each primer. Ct 
values were plotted against log cDNA dilution to 
construct standard curves for each target gene. After 
each RT-PCR, a melting profile was created and 
agarose gel electrophoresis was conducted in each 
sample to rule out nonspecific PCR products and 
primer dimers. The comparative Ct method was 
employed for the relative quantification of gene 
expression. The mRNA concentration for each gene 
was expressed as ng of mRNA per average ng of 
housekeeping mRNAs. The cDNA from individual 
cell experiments was analyzed in triplicate RT-PCR 
studies.  
Table 1. Primer sequences for the amplification of cDNA by 
real-time PCR. 



































R software (version 2.9.2, Auckland, New 
Zealand) was used for data analyses. Mean values 
(±standard deviation) were calculated for each 
variable. A two-way repeated-measures analysis of 
variance (ANOVA) was performed to analyze the 
effects on proliferation, cell cycle, apoptosis/necrosis 
induction, and gene expression, considering treatment 
(celecoxib), time (24 h), and concentration (0.75, 2, or 5 
μM). When significant interactions were identified, 
the Bonferroni correction was applied for planned 
pair-wise comparisons. P ≤ 0.05 was considered 
significant. Antigenic profiles were compared using 
the Student’s t-test. P ≤ 0.05 was considered 
statistically significant in all tests. At least three 
experiments were performed in all assays and for each 
culture. 
Results  
Effect of celecoxib on osteoblast proliferation 
Figure 1 depicts the effect of celecoxib on cell 
proliferation after 24 h of treatment with doses of 0.75, 
2, or 5 µM. No significant changes in the proliferative 
capacity of osteoblasts were observed after treatment 
at any assayed dose of the drug.  
 
 
Figure 1. Effects of different celecoxib doses (0.75, 2, or 5 μM) on osteoblast 
proliferation after 24 h of treatment. Data are expressed as means +/± SD. Analysis of 
variance was used to compare data between each treatment and control culture. 




Effect of celecoxib on osteoblast cell cycle 
Treatment with 0.75, 2, or 5 μM celecoxib for 24 h 
produced no significant changes in osteoblast cell 
cycle, finding similar cell percentages in G0/G1, 




Figure 2. Effects of celecoxib on cell cycle determined by flow cytometry. Cultured 
cells were treated for 24 h with 0.75, 2, or 5 μM celecoxib. The control group was not 
treated. G0/G1, S, and G2/M represent the percentage of cells distributed among 
these phases after treatment, as determined by flow cytometry. Experiments were 
repeated at least three times. 
 
Effect of celecoxib on osteoblast in apoptosis 
No signs of cell apoptosis and/or necrosis were 
detected after osteoblast treatment with 0.75, 2, or 5 
μM celecoxib for 24 h (Table 2). 
 
Table 2. Results of apoptosis assay in cultured cells treated for 24 
h with celecoxib doses of 0.75, 2, or 5 μM. 
 Necrotic cells  Viable cells  Apoptotic cells  
Mean P Value SD Mean P Value SD Mean P Value SD 
Control 0,633 - 0,321 91,233 - 10,404 8,133 - 10,082 
0,75 0,466 0,519 0,251 91,666 0,952 5,396 7,866 0,970 5,492 
2 0,366 0,230 0,057 83,566 0,295 3,655 16,066 0,269 3,611 
 
 
Effect of celecoxib on the expression of 
RUNX2, ALP, OSX, and OSC genes 
Figures 3 and 4 depict the q-RT-PCR results for 
the expression of osteoblast differentiation makers 
RUNX2, ALP, OSX, and OSC. After 24 h of treatment 
at a dose of 2 or 5 µM, osteoblast expression of RUNX2 
(figure 3A) and OSC (figure 3B) was significantly 
lower versus controls (Figure 3).  
 However, no changes in the expression of these 
markers were observed at the lowest dose (0.75 µM). 
ALP (Figure 4A) and OSX (Figure 4B) expression did 
not change after treatment with celecoxib at any 
assayed dose (Figure 4). 
Effect of celecoxib on phenotypic profile 
Expression of CD54, CD80, CD86, or HLA-DR 
genes did not significantly differ between cells treated 
for 24 h with 0.75, 2, or 5 µM celecoxib and untreated 
control cells (Figure 5). 
 
Figure 3. Expression of RUNX2 (3A) and OSC (3B) genes after 24 h treatment with 0.75, 2, or 5 µM. Data expressed as percentage expression with respect to control ± SD. 
(*** P ≤ 0.0001; ** P ≤ 0.01; * P ≤ 0.05). 
 
Figure 4. Expression of ALP (4A) and OSX (4B) genes after 24 h treatment with 0.75, 2, or 5 µM. Data expressed as percentage expression with respect to control ± SD. (*** 
P ≤ 0.0001; ** P ≤ 0.01; * P ≤ 0.05). 






Figure 5. Expression of CD54, CD80, CD86, and HLA-DR genes by cells treated for 
24 h with celecoxib (0.75, 2, or 5 μM). Data are expressed as percentage expression 
with respect to control ±SD. 
 
Discussion 
Treatment of primary culture human osteoblasts 
with therapeutic doses of celecoxib, a COX-2 selective 
NSAID, had no significant effects on their antigenic 
profile, growth, proliferation, or cell cycle and 
produced no signs of cell death. However, this 
treatment reduced the gene expression of RUNX2 and 
OSC, two biological markers with an important role in 
osteoblast differentiation, whereas no changes were 
observed in the expression of ALP or OSX. These 
results suggest that celecoxib, unlike other NSAIDs 
(7), acts on the expression of some of the genes 
involved in cell differentiation but does not affect 
other cell parameters such as growth or antigen 
expression. 
The finding that celecoxib at 0.75, 2, or 5 µM 
(within the therapeutic range) has no effect on 
osteoblast growth is in line with previously published 
results. For instance, proapoptotic effects were 
observed after the treatment of MG63 human 
osteoblast cells with celecoxib at a dose of 50 µM but 
not at a dose of 2 or 10 µM (20), and no changes in the 
proliferation or viability of the murine pre-osteoblastic 
cell line MC3T3-E1 were observed after treatment with 
celecoxib at a dose of 20 µM (21). However, celecoxib 
at doses of 0.1 or 1 µM was found to inhibit cell 
proliferation and arrest the cell cycle in G0/G1 phase 
in cultured human osteoblasts (4) and in mesenchymal 
cells derived from mouse bone marrow (22). This last 
effect has been reported for other non-selective 
NSAIDs, in which the drug dose plays an important 
role (5,6,23).  
The above effects of celecoxib on osteoblasts in 
vitro are closely related to observations in 
experimental animals. Thus, Kasukawa et al. (15) 
treated ovariectomized mice at a dose of 4 mg/kg for 
four weeks and found no change in bone formation 
but observed an effect on C- telopeptide, a marker 
related to resorption, a function carried out at bone 
level by osteoclasts. Liu et al. (24) treated Sprague 
Dawley rats with daily doses of 50 mg/kg celecoxib for 
two weeks and also observed no significant effect on 
bone formation.  
Celecoxib does not appear to compromise bone 
healing, given that bone fusion was not altered by its 
administration at 10 mg/kg/day for eight weeks to 
rabbits after posterolateral intertransverse arthrodesis 
(25). In another study, Brown et al. (26) treated male 
rats with 3 mg/kg/day celecoxib or 1 mg/kg/day 
indomethacin for four or eight weeks and found no 
difference in healing versus controls for the 
celecoxib-treated rats but a delay in healing for the 
indomethacin-treated animals. Osteoblasts are directly 
involved in bone fracture healing, being the cells 
responsible for bone formation and repair during this 
process (27,28). 
Osteoblasts have a characteristic antigenic 
profile, including antigens whose expression is 
modulated by the degree of cell maturation and/or 
the presence of certain biomolecules such as 
proinflammatory cytokines (29,30). Various NSAIDs 
have been found to modulate the expression of CD54, 
CD80, and HLA-DR (5,23,31). However, celecoxib 
treatment did not change the expression of these 
markers at any dose assayed in the present study.  
Although no effect on osteoblast growth or 
antigenic profile was observed, celecoxib doses of 2 
and 5 µM inhibited the gene expression of 
differentiation markers RUNX2 and OSC but not ALP 
or OSX. Matsuyama et al. (21) reported that celecoxib 
doses between 0.02 and 20 µM inhibit osteoblast 
differentiation in the MC3T3-E1 line but do not alter 
cell viability, indicating that negative effects on bone 
tissue at doses above 0.02 µM may be attributable to 
the inhibition of osteoblast differentiation. Nagano et 
al. (32) found that 50 µM celecoxib can inhibit the 
expression of RUNX2 mRNA in the same cell line 
(MC3T3-E1).  
OSC is a peptide hormone secreted by 
osteoblasts during bone formation at a late stage of 
osteoblast differentiation, and it participates in bone 
mineralization and osteoclast activity regulation (33). 
It is transcribed by the RUNX2/CBFA1 complex (34). 
This raises the question whether the decrease in OSC 
expression is directly caused by the celecoxib 
treatment or is indirectly produced by its inhibitory 
effect on the expression of RUNX2. Celecoxib was 
found to negatively affect bone formation in mice, 
observing a reduced expression of OSC mRNA in 
bone marrow samples from those administered with 
30 mg/kg celecoxib twice daily for five days (14).  
Selective and non-selective NSAIDs are used in 
the treatment of heterotopic ossification, which can 
appear after surgery, especially arthroplasty. This 




ossification of soft tissue results from an abnormal 
differentiation to bone cells of mesenchymal stem 
cells. NSAIDs are used to inhibit the bone 
differentiation of progenitors and prevent this surgical 
complication (35–38). These data may be related to our 
finding of a celecoxib-induced decrease in the gene 
expression of markers such as RUNX2 and OSC. 
However, celecoxib treatment was found to reduce 
inflammation in rats with collagen-induced arthritis, 
and high doses of this drug prevented bone loss 
adjacent to inflamed joints and significantly decreased 
bone resorption but had no impact on bone formation 
(39). The authors concluded that celecoxib had a 
preventive effect on both growth plate destruction and 
bone loss adjacent to inflamed joints in this arthritis 
model. 
In summary, our study shows that therapeutic 
doses of celecoxib, ranging from 0.75 to 5 µM, have no 
adverse effects on osteoblast growth or antigen 
expression but reduce the gene expression of RUNX2 
and OSC. It is not possible to establish whether this 
reduction affects physiological bone development 
given the absence of changes in the expression of ALP 
or OSX, also involved in differentiation. Further 
studies are required to determine whether celecoxib 
interferes with the maturation of osteoblasts and 
therefore with their function at bone tissue level. 
Nevertheless, our results indicate that this NSAID is a 
good option for analgesic and anti-inflammatory 
therapy during bone tissue repair. 
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